Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.

abstract：:Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

journal_title：Expert opinion on pharmacotherapy

authors： Mukherjee A,Dhadda AS,Shehata M,Chan S

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

journal_title：Expert opinion on pharmacotherapy

authors： Striano P,Belcastro V

更新日期：2013-07-01 00:00:00

abstract：:The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease. Pharmacotherapies for opioid addiction include opioid agonists, partial agonists, opioid antagonists, and alpha-2-adrenergic agonists, which are targeted toward either detoxification ...

journal_title：Expert opinion on pharmacotherapy

authors： Stotts AL,Dodrill CL,Kosten TR

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and tra...

journal_title：Expert opinion on pharmacotherapy

authors： Stull C,Lavery MJ,Yosipovitch G

更新日期：2016-01-01 00:00:00

abstract：:Although panic disorder usually emerges in early to middle adulthood, adults with panic disorder often retrospectively report that their panic symptoms began in childhood or early adolescence. The majority of these juvenile cases are being misdiagnosed, and/or do not come to clinical attention. Awareness of early-onse...

journal_title：Expert opinion on pharmacotherapy

authors： Masi G,Pari C,Millepiedi S

更新日期：2006-04-01 00:00:00

abstract：INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...

journal_title：Expert opinion on pharmacotherapy

authors： Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

更新日期：2016-07-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Statins are widely accepted as the drugs of choice for achieving increasingly stringent low-density lipoprotein cholesterol (LDL-C) goals for dyslipidemic patients. However, when making treatment decisions, outcomes data from clinical trials are of greater importance than LDL-C-lowering ability....

journal_title：Expert opinion on pharmacotherapy

authors： Weart CW,Hogan RJ

更新日期：2011-01-01 00:00:00

abstract：INTRODUCTION:Heart failure (HF) treatment attracts a share of intensive research because of its poor HF prognosis. In the past decades, the prognosis of HF has improved considerably, mainly as a consequence of the progress that has been made in the pharmacological management of HF. AREAS COVERED:This article reviews t...

journal_title：Expert opinion on pharmacotherapy

authors： Kaldara E,Sanoudou D,Adamopoulos S,Nanas JN

更新日期：2015-01-01 00:00:00

abstract：:Consensus guidelines for the management of HIV infection recommend the use of two nucleoside analogues in combination with either a non-nucleoside reverse transcriptase inhibitor or a ritonavir-boosted protease inhibitor in therapy-naive patients. As adherence is crucial for treatment success, regimens with fewer pill...

journal_title：Expert opinion on pharmacotherapy

authors： Waters L,Moyle G

更新日期：2006-12-01 00:00:00

abstract：INTRODUCTION:Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a range of phosphate binders designed to keep serum phospha...

journal_title：Expert opinion on pharmacotherapy

authors： Locatelli F,Dimkovic N,Spasovski G

更新日期：2014-07-01 00:00:00

abstract：:The use of antihypertensive therapy is an evolving paradigm. Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clinical guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clin...

journal_title：Expert opinion on pharmacotherapy

authors： Calhoun DA

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

journal_title：Expert opinion on pharmacotherapy

authors： Moore BR,Davis TME

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Hodgkin lymphoma (HL) is a lymphoid malignancy with an incidence of 2 - 3/100,000/year. Young adults are most often affected. Due to the development of highly active multi-agent chemotherapy protocols and the optimization of radiotherapy (RT) fields and doses, HL has become one of the malignancies with the...

journal_title：Expert opinion on pharmacotherapy

authors： Eichenauer DA,Böll B,Diehl V

更新日期：2014-06-01 00:00:00

abstract：:Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

journal_title：Expert opinion on pharmacotherapy

authors： Rickels K

更新日期：2004-07-01 00:00:00

abstract：:Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...

journal_title：Expert opinion on pharmacotherapy

authors： Foschi M,Lugaresi A

更新日期：2019-08-01 00:00:00

abstract：INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

journal_title：Expert opinion on pharmacotherapy

authors： Stirnimann G

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

journal_title：Expert opinion on pharmacotherapy

authors： Sipos JA,Mazzaferri EL

更新日期：2008-10-01 00:00:00

abstract：INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

journal_title：Expert opinion on pharmacotherapy

authors： Choi SH,Koh Y

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeabi...

journal_title：Expert opinion on pharmacotherapy

authors： Apte RS

更新日期：2008-02-01 00:00:00

abstract：:Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...

journal_title：Expert opinion on pharmacotherapy

authors： Li HQ,Chi S,Dong Q,Yu JT

更新日期：2019-09-01 00:00:00

abstract：INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

journal_title：Expert opinion on pharmacotherapy

authors： Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

更新日期：2013-08-01 00:00:00

abstract：:Dermatomyositis is traditionally classified as one of the idiopathic inflammatory myopathies. The traditional approach to the management of patients with dermatomyositis focuses predominantly on end points related to the systemic manifestations of this disorder, especially proximal muscle weakness resulting from myosi...

journal_title：Expert opinion on pharmacotherapy

authors： Sontheimer RD

更新日期：2004-05-01 00:00:00

abstract：:Phosphorus binders are used in patients with kidney failure because of the incomplete removal of phosphorus with dialysis and the inability to exclude phosphorus from the diet. Aluminium was the initial phosphorus binder used, but was replaced by calcium-containing binders because of the development of aluminium toxic...

journal_title：Expert opinion on pharmacotherapy

authors： Bleyer AJ

更新日期：2003-06-01 00:00:00

abstract：INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

journal_title：Expert opinion on pharmacotherapy

authors： Flynn MJ,Larkin JMG

更新日期：2017-10-01 00:00:00

abstract：:Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

journal_title：Expert opinion on pharmacotherapy

authors： Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

更新日期：2001-11-01 00:00:00

abstract：INTRODUCTION:The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and has contributed to over 650,000 deaths. This review synthesizes the literature on COVID-19 pharmacotherapy to inform practice and policymaking. A...

journal_title：Expert opinion on pharmacotherapy

authors： Khan S,Gionfriddo MR,Cortes-Penfield N,Thunga G,Rashid M

更新日期：2020-10-01 00:00:00

abstract：:The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischae...

journal_title：Expert opinion on pharmacotherapy

authors： Ly JV,Zavala JA,Donnan GA

更新日期：2006-08-01 00:00:00

abstract：INTRODUCTION:Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of ...

journal_title：Expert opinion on pharmacotherapy

authors： Turkistani A,Marsh S

更新日期：2012-06-01 00:00:00

abstract：:Pain may produce metabolic changes after surgery, which may contribute to further morbidity. A variety of medicines and techniques can be used to successfully treat pain. It is postulated that improved analgesia leads to improved outcomes, although analgesics may also contribute to morbidity. This article reviews the ...

journal_title：Expert opinion on pharmacotherapy

authors： Engoren M

更新日期：2003-09-01 00:00:00

abstract：INTRODUCTION:Acute diarrhea remains a major problem in children and is associated with substantial morbidity, mortality and costs. While vaccination against rotavirus could reduce the burden of the disease, the persistent impact of intestinal infections requires effective treatment in adjunct to oral rehydration soluti...

journal_title：Expert opinion on pharmacotherapy

authors： Guarino A,Dupont C,Gorelov AV,Gottrand F,Lee JK,Lin Z,Lo Vecchio A,Nguyen TD,Salazar-Lindo E

更新日期：2012-01-01 00:00:00